BRAF and colorectal carcinoma: Thus the combination of a BRAF inhibitor with an EGFR monoclonal antibody enhances treatment efficacy in patients with BRAF V600E mCRC.8, 9, 10 The phase III BEACON CRC trial, involving 665 patients with BRAF V600E mCRC in the second or third line of treatment, demonstrated that the combination of encorafenib and cetuximab with or without binimetinib significantly improved objective response rate (ORR) and overall survival (OS) compared with standard of care (irinotecan-based chemotherapy plus cetuximab), with an acceptable safety profile.11